Boothbay Fund Management’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-191,900
Closed -$921K 1832
2023
Q4
$921K Sell
191,900
-60,400
-24% -$370K 0.02% 757
2023
Q3
$1.83M Buy
252,300
+171,000
+210% +$1.37M 0.04% 530
2023
Q2
$604K Buy
+81,300
New +$639K 0.01% 1014
2021
Q2
Sell
-210
Closed -$3.81M 2031
2021
Q1
$3.81M Sell
210
-147
-41% -$29.3K 0.14% 147
2020
Q4
$3.98M Sell
357
-79
-18% -$8.4K 0.15% 125
2020
Q3
$4.72M Buy
436
+229
+111% +$27.9K 0.29% 70
2020
Q2
$1.73M Buy
+207
New +$7.92K 0.12% 238

Other funds holding NVAX

Boothbay Fund Management's NVAX Position: Q1 2024 in Review

Boothbay Fund Management sold out of Novavax (NVAX) in Q1 2024, closing a stake of 53,506 shares — an estimated $257K sold.

Boothbay Fund Management first reported a position in NVAX in Q2 2017 and held it in 5 quarters. The position peaked at $724K in Q3 2023. 201 funds tracked by Wall St. Rank hold NVAX as of Q1 2024.

  • Boothbay Fund Management reported no remaining Novavax position as of Q1 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 53,506 Novavax shares in Q1 2024, an estimated $257K.
  • Boothbay Fund Management first reported a position in Novavax in Q2 2017 and held it in 5 quarters.
  • Boothbay Fund Management's Novavax position peaked at $724K in Q3 2023.
  • 201 funds tracked by Wall St. Rank held Novavax as of Q1 2024.

Based on Boothbay Fund Management's 13F filing for Q1 2024, filed 15 May 2024.